NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

Phase 2

Active, not recruiting

Conditions: Sarcoma G3
Stage II Soft Tissue Sarcoma AJCC v7
Soft Tissue Sarcoma of the Trunk and Extremities
Stage I Soft Tissue Sarcoma AJCC v7
Undifferentiated Pleomorphic Sarcoma
Sarcoma G2
Leiomyosarcoma
Liposarcoma
Soft Tissue Sarcoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Magnetic Resonance Imaging
Radiation: Radiation Therapy
Biological: Talimogene Laherparepvec

First Posted Date: 2016-10-05

Last Posted Date: 2025-05-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT02923778

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States

and more 14 locations

Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer

Phase 2

Completed

Conditions: Stage III Rectal Cancer AJCC v7
Rectal Adenocarcinoma
Stage II Rectal Cancer AJCC v7

Interventions: Drug: Capecitabine
Drug: Fluorouracil
Radiation: Intensity-Modulated Radiation Therapy
Drug: Leucovorin
Drug: Oxaliplatin
Biological: Pembrolizumab
Drug: Veliparib

First Posted Date: 2016-10-03

Last Posted Date: 2024-04-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 363

Registration Number: NCT02921256

Locations: 🇺🇸
Island Urology, Honolulu, Hawaii, United States
🇺🇸
Queen's Medical Center, Honolulu, Hawaii, United States
🇺🇸
Straub Clinic and Hospital, Honolulu, Hawaii, United States

and more 645 locations

Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer

Phase 2

Completed

Conditions: Cervical Adenocarcinoma
Recurrent Cervical Carcinoma
Stage IV Cervical Cancer AJCC v6 and v7
Cervical Adenosquamous Carcinoma
Stage IVA Cervical Cancer AJCC v6 and v7
Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Stage IVB Cervical Cancer AJCC v6 and v7

Interventions: Drug: Atezolizumab
Biological: Bevacizumab
Other: Laboratory Biomarker Analysis

First Posted Date: 2016-10-03

Last Posted Date: 2023-02-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 11

Registration Number: NCT02921269

Locations: 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

and more 19 locations

ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment

Phase 2

Terminated

Conditions: Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Oral Cavity Neoplasm
Stage 0 Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7
Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7
Stage 0 Oral Cavity Squamous Cell Carcinoma American Joint Committee on Cancer (AJCC) v6 and v7
Stage I Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7
Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7

Interventions: Other: Laboratory Biomarker Analysis
Drug: Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet
Other: Pharmacological Study
Other: Placebo

First Posted Date: 2016-09-28

Last Posted Date: 2023-03-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 6

Registration Number: NCT02917629

Locations: 🇺🇸
University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

and more 1 locations

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Phase 3

Active, not recruiting

Conditions: Lynch Syndrome
DNA Repair Disorder
Colon Adenocarcinoma
Stage III Colon Cancer AJCC v8

Interventions: Drug: Atezolizumab
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Fluorouracil
Drug: Leucovorin Calcium
Procedure: Magnetic Resonance Imaging
Drug: Oxaliplatin
Other: Quality-of-Life Assessment

First Posted Date: 2016-09-23

Last Posted Date: 2025-05-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 700

Registration Number: NCT02912559

Locations: 🇺🇸
Bronson Battle Creek, Battle Creek, Michigan, United States
🇺🇸
Oakland Medical Group, Royal Oak, Michigan, United States
🇺🇸
Saint Ann's Hospital, Westerville, Ohio, United States

and more 1046 locations

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

Phase 1

Active, not recruiting

Conditions: Primary Effusion Lymphoma
B-Cell Neoplasm

Interventions: Drug: Lenalidomide
Drug: Rituximab
Drug: Prednisone
Drug: Etopside
Drug: Doxorubicin
Drug: Vincristine
Drug: Cyclophosphamide

First Posted Date: 2016-09-22

Last Posted Date: 2024-10-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT02911142

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists

Completed

Conditions: Thyroid Cancer
Brain Cancer
Circulatory Disease
Breast Cancer

First Posted Date: 2016-09-22

Last Posted Date: 2020-05-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 229

Registration Number: NCT02911155

Locations: 🇺🇸
University of Minnesota, School of Public Health Environmental Health Sciences, Minneapolis, Minnesota, United States

Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Extensive Stage Lung Small Cell Carcinoma

Interventions: Drug: Carboplatin
Drug: Cediranib
Drug: Cediranib Maleate
Drug: Cisplatin
Drug: Etoposide
Drug: Olaparib

First Posted Date: 2016-09-14

Last Posted Date: 2023-10-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 9

Registration Number: NCT02899728

Locations: 🇺🇸
Los Angeles County-USC Medical Center, Los Angeles, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States

and more 21 locations

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

Phase 1

Completed

Conditions: Unresectable High Grade Fallopian Tube Serous Adenocarcinoma
Metastatic Primary Peritoneal Serous Adenocarcinoma
Platinum-Resistant Fallopian Tube Carcinoma
Platinum-Resistant Primary Peritoneal Carcinoma
Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma
Recurrent Triple-Negative Breast Carcinoma
Refractory Primary Peritoneal Serous Adenocarcinoma
Unresectable Primary Peritoneal Serous Adenocarcinoma
Metastatic High Grade Fallopian Tube Serous Adenocarcinoma
Metastatic Malignant Solid Neoplasm

Interventions: Drug: Olaparib
Drug: Onalespib

First Posted Date: 2016-09-13

Last Posted Date: 2023-04-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 28

Registration Number: NCT02898207

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

and more 5 locations

Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery

Phase 2

Completed

Conditions: Pancreatic Neuroendocrine Tumor G1
Pancreatic Neuroendocrine Tumor G2
Refractory Pancreatic Neuroendocrine Carcinoma

Interventions: Drug: Sapanisertib

First Posted Date: 2016-09-09

Last Posted Date: 2023-10-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 13

Registration Number: NCT02893930

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Bhadresh Nayak MD PC-Sterling Heights, Sterling Heights, Michigan, United States
🇺🇸
Central Care Cancer Center - Bolivar, Bolivar, Missouri, United States

and more 400 locations

Home Terms & Conditions Privacy Policy